Reduced levels of miR-218 have been reported in breast cancer-derived tumor tissues with increased cisplatin resistance as well as in a cisplatin-resistant MCF7 breast cancer subline, which was explained by the regulation of the tumor suppressor BRCA1 by miR-218 [121]. This evidence concerns the gene BRCA1 and breast carcinoma.